Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100273193 | 10027319 | 3 | F | 201301 | 20140805 | 20140321 | 20151231 | EXP | US-ASTELLAS-2014US002718 | ASTELLAS | 72.69 | YR | F | Y | 0.00000 | 20151231 | CN | GB | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100273193 | 10027319 | 1 | PS | Erlotinib | ERLOTINIB | 1 | Oral | 1053701CW, 77163P1CW | 21743 | 150 | MG | TABLET | QD | ||||||
| 100273193 | 10027319 | 2 | SS | Erlotinib | ERLOTINIB | 1 | Oral | 1053701CW, 77163P1CW | 21743 | 100 | MG | TABLET | QD | ||||||
| 100273193 | 10027319 | 3 | SS | Erlotinib | ERLOTINIB | 1 | Oral | 1053701CW, 77163P1CW | 21743 | 75 | MG | TABLET | QD | ||||||
| 100273193 | 10027319 | 4 | C | VITAMIN D3 | CHOLECALCIFEROL | 1 | Unknown | 0 | 4000 | DF | FORMULATION UNKNOWN | QD | |||||||
| 100273193 | 10027319 | 5 | C | MYLANTA | ALUMINUM HYDROXIDEDIMETHICONEMAGNESIUM HYDROXIDE | 1 | Unknown | 0 | FORMULATION UNKNOWN | ||||||||||
| 100273193 | 10027319 | 6 | C | ANALGESICS | UNSPECIFIED INGREDIENT | 1 | Unknown | 0 | FORMULATION UNKNOWN | ||||||||||
| 100273193 | 10027319 | 7 | C | TYLENOL | ACETAMINOPHEN | 1 | Unknown | UNK UNK, UNKNOWN FREQ. | U | 0 | FORMULATION UNKNOWN | ||||||||
| 100273193 | 10027319 | 8 | C | MAGNESIUM HYDROXIDE W/SIMETHICONE | 2 | Unknown | UNK UNK, UNKNOWN FREQ. | U | 0 | FORMULATION UNKNOWN |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 100273193 | 10027319 | 1 | Non-small cell lung cancer |
| 100273193 | 10027319 | 2 | Lung carcinoma cell type unspecified stage IV |
| 100273193 | 10027319 | 4 | Vitamin D decreased |
| 100273193 | 10027319 | 5 | Reflux gastritis |
| 100273193 | 10027319 | 6 | Pain |
| 100273193 | 10027319 | 7 | Product used for unknown indication |
| 100273193 | 10027319 | 8 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 100273193 | 10027319 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 100273193 | 10027319 | Acne | |
| 100273193 | 10027319 | Alopecia | |
| 100273193 | 10027319 | Conjunctivitis | |
| 100273193 | 10027319 | Diarrhoea | |
| 100273193 | 10027319 | Eye discharge | |
| 100273193 | 10027319 | Eye irritation | |
| 100273193 | 10027319 | Glossodynia | |
| 100273193 | 10027319 | Hair texture abnormal | |
| 100273193 | 10027319 | Lip swelling | |
| 100273193 | 10027319 | Madarosis | |
| 100273193 | 10027319 | Malignant neoplasm progression | |
| 100273193 | 10027319 | Nasal dryness | |
| 100273193 | 10027319 | Pruritus | |
| 100273193 | 10027319 | Rash | |
| 100273193 | 10027319 | Skin burning sensation | |
| 100273193 | 10027319 | Tongue eruption | |
| 100273193 | 10027319 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 100273193 | 10027319 | 1 | 20121228 | 0 |